文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重组人可溶性血栓调节蛋白治疗特发性肺纤维化急性加重:一项全国性观察性研究

Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study.
PubMed 文献 · J Intensive Care · 2022-03-09
一句话结论在需机械通气的特发性肺纤维化急性加重患者中,重组人可溶性血栓调节蛋白联合大剂量甲泼尼龙与单用甲泼尼龙相比,院内死亡率无显著差异(76.9% vs 75.9%,OR 1.15,95%CI 0.71-1.84,p=0.57)。

该研究基于日本诊断程序组合数据库2014年1月1日至2018年3月31日的数据,回顾性纳入接受大剂量甲泼尼龙治疗并机械通气的成人特发性肺纤维化急性加重患者2814例,分为单用大剂量甲泼尼龙组(n=2602)和重组人可溶性血栓调节蛋白联合大剂量甲泼尼龙组(n=212)。采用稳定化逆概率治疗加权(IPTW)比较结局,主要终点院内死亡率在两组分别为75.9%和76.9%,OR 1.15(95%CI 0.71-1.84;p=0.57),无显著差异;14天和28天死亡率、出血事件及住院时间等次要终点亦无显著差异。结论认为,在发生严重呼吸衰竭的特发性肺纤维化急性加重患者中,大剂量甲泼尼龙基础上加用重组人可溶性血栓调节蛋白与更好的结局无关。

要点

  • 研究纳入2814例接受大剂量甲泼尼龙并机械通气的特发性肺纤维化急性加重成人患者,rTM组212例,单用甲泼尼龙组2602例。
  • 主要终点院内死亡率:单用甲泼尼龙组75.9% vs rTM组76.9%,稳定化IPTW后OR 1.15(95%CI 0.71-1.84;p=0.57),无显著差异。
  • 次要终点14天死亡率、28天死亡率、出血事件及住院时间在两组间均无显著差异。
  • 在发生严重呼吸衰竭的特发性肺纤维化急性加重患者中,大剂量甲泼尼龙基础上加用rTM与更好的结局无关。

适用人群与场景

  • 日本诊断程序组合数据库中2014年1月1日至2018年3月31日的成人特发性肺纤维化患者,入院时接受大剂量甲泼尼龙治疗并机械通气(n=2814)。

处置流程与药物剂量

  • 单用大剂量甲泼尼龙组(n=2602)接受大剂量甲泼尼龙治疗。
  • rTM组(n=212)接受重组人可溶性血栓调节蛋白联合大剂量甲泼尼龙治疗。

研究设计与关键结果

  • 研究类型为回顾性全国性观察性研究,数据来自日本诊断程序组合数据库,纳入2814例接受大剂量甲泼尼龙并机械通气的成人特发性肺纤维化急性加重患者,分为单用大剂量甲泼尼龙组(n=2602)和rTM联合大剂量甲泼尼龙组(n=212),采用稳定化逆概率治疗加权(IPTW)比较结局。
  • 主要终点院内死亡率:单用甲泼尼龙组75.9% vs rTM组76.9%,稳定化IPTW后OR 1.15(95%CI 0.71-1.84;p=0.57),无显著差异。
  • 次要终点14天死亡率、28天死亡率、出血事件及住院时间在两组间均无显著差异。

证据类型、等级与局限

  • 证据类型:回顾性全国性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在发生严重呼吸衰竭的特发性肺纤维化急性加重患者中,大剂量甲泼尼龙基础上加用重组人可溶性血栓调节蛋白与更好的结局无关(院内死亡率76.9% vs 75.9%,OR 1.15,95%CI 0.71-1.84;p=0.57)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is the leading cause of death among patients with IPF. However, there is no established treatment for this condition. Hence, we aimed to investigate the effectiveness and safety of recombinant human soluble thrombomodulin (rTM) for the treatment of AE-IPF.

METHODS: Data were retrospectively collected from the Japanese Diagnosis Procedure Combination database from 1 January 2014 to 31 March 2018. We identified adult patients with IPF who received high-dose methylprednisolone (mPSL) therapy and mechanical ventilation upon admission. Eligible patients (n = 2814) were divided into those receiving high-dose mPSL alone (mPSL alone group, n = 2602) and rTM combined with high-dose mPSL (rTM group, n = 212). A stabilised inverse probability of treatment weighting (IPTW) using propensity scores was performed to compare outcomes between the two groups. The primary outcome was in-hospital mortality, and the secondary outcomes were 14- and 28-day mortality, bleeding events and length of hospital stay.

RESULTS: The in-hospital mortality rates of the mPSL alone and rTM groups were 75.9% and 76.9%, respectively. The results did not significantly differ between the two groups after performing a stabilised IPTW. The odds ratio of the rTM group compared to the mPSL alone group was 1.15 (95% confidence interval: 0.71-1.84; p = 0.57). Moreover, the secondary outcomes did not differ significantly between the two groups.

CONCLUSIONS: In patients with AE-IPF who developed severe respiratory failure, rTM in addition to high-dose mPSL was not associated with a better outcome.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Awano N, Jo T, Izumo T, et al. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study. J Intensive Care. 2022. PMID: 35264250. doi:10.1186/s40560-022-00608-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。